(Q46099197)

19 December 2017

title

Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor (English)

1 reference

19 December 2017

author name string

Krystyna Tatarkiewicz

1

1 reference

19 December 2017

Emmanuel J Sablan

2

1 reference

19 December 2017

Clara J Polizzi

3

1 reference

19 December 2017

Christiane Villescaz

4

1 reference

19 December 2017

David G Parkes

5

1 reference

19 December 2017

publication date

29 January 2014

1 reference

19 December 2017

American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

published in

1 reference

19 December 2017

volume

306

1 reference

19 December 2017

issue

7

1 reference

19 December 2017

page(s)

R490-8

1 reference

19 December 2017

Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Pharmacology, physiology, and mechanisms of incretin hormone action

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Investigation of exenatide elimination and its in vivo and in vitro degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Discovery of dual-action membrane-anchored modulators of incretin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Gastric inhibitory polypeptide does not inhibit gastric emptying in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Exendin-4 potently decreases ghrelin levels in fasting rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Cell signalling of the GLP-1 action in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00495.2013

10.1152/AJPREGU.00495.2013

21 January 2018

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017